

Aqua Bio Technology ASA: New share capital registered

Reference is made to the private placement of 48,432,000 new shares in Aqua Bio Technology ASA (the "**Company**") placed in March 2025 (the "**Private Placement**") and to the subsequent offering carried out in March and April 2025 (the "**Subsequent Offering**"), where a total of 4,111,975 new shares were allocated (together with the new shares in the Private Placement, the "**New Shares**"). Reference is further made to the resolution by an extraordinary general meeting on 25 July 2025 to increase the Company's share capital in connection with the Private Placement and the Subsequent Offering, and furthermore to the resolution by an extraordinary general meeting on 7 November 2025 to reduce the Company's share capital by reduction of the par value of the Company's shares to NOK 0.10 per share (the "**Share Capital Decrease**").

Through the Private Placement, the Company has issued 48,432,000 New Shares at a subscription price of NOK 0.50 per New Share, each with a par value of NOK 0.10. Consequently, the share capital of the Company was increased with NOK 4,843,200 through the Private Placement.

Through the Subsequent Offering, the Company has issued 4,111,975 New Shares at a subscription price of NOK 0.50 per New Shares, each with a par value of NOK 0.10. Consequently, the share capital of the Company was increased with NOK 411,197.50 through the Subsequent Offering.

Through the Share Capital Decrease, the Company's share capital was decreased with NOK 261,246, 580.80, through reduction of the par value of the Company's shares from NOK 2.50 to NOK 0.10 per share.

Following registration of the share capital changes described above, the Company's new share capital is NOK 16,139,671.70 divided by 161,396,717 shares, each with a par value of NOK 0.10.

The New Shares will initially be registered with the VPS and delivered to the subscribers in the Private Placement and the Subsequent Offering on a separate, non-tradable ISIN, pending approval and publication of a listing prospectus. Such listing prospectus is currently expected to be approved and published by end of December 2025.

Contacts

Kristian Flaten

CEO & CFO

Aqua Bio Technology ASA

Phone: +47 9509 2322

Email: kf@aquabiotech.no

About Us

Aqua Bio Technology ASA (ABTEC) is a technology and distribution group in skincare and nonfood. The group has distribution towards B2C and B2B, and offers freight, customs, and logistics services. The group also develops sustainable biotechnology for use in skincare products. Aqua Bio Technology is listed on Euronext Expand Oslo.

This notice is published by Kristian Flaten on the listed date and time.

*This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR Article 17.
The information was submitted for publication at 2025-11-11 15:00 CET.*